Introduction
Investi gations of immunological and clinical outcomes for patients after virological failure to all three original antiretroviral classes [1] [2] [3] [4] have shown the eff ects of widespread antiviral resistance on prognosis, 4 the importance of maintaining CD4 cell counts of 200 cells per μL or higher, 2 and the need to continue antiretroviral therapy even when viral load is not controlled. 2, 5, 6 Improved clinical outcomes were reported in individuals with triple-class virological failure (TCVF) dependent on the number of new drugs started, probably owing to more favourable resistance profi les.
1, 3 However, most people in these early studies started antiretroviral therapy with only one or two drugs, which conferred a high risk of resistance to nucleoside reversetranscriptase inhibitors (NRTIs). Now, all patients starting anti retroviral therapy are recommended to do so with potent combination regimens of three or more drugs.
Although current regimens have led to sustained viral suppression in an increasing proportion of people, 7 some individuals do still have virological failure to drugs from the three original classes. As part of the Pursuing Later Treatment Option II (PLATO II) project, we reported a low rate of TCVF (3·4% by 5 years) 8 in participants in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) database who started antiretroviral therapy including a non-NTRI (NNRTI) or a ritonavir-boosted protease inhibitor from 1998. Virological and clinical outcomes for people who had TCVF, and in particular how these outcomes changed with time, have not been widely studied. 9 We aimed to assess trends in virological and clinical outcomes over the past decade in people with TCVF.
Methods

Study design and procedures
We analysed data obtained from participants in the PLATO II project from the COHERE database 10 (a collaboration of 33 observational cohort studies of HIV in Europe). The PLATO II project contains data from 28 participating cohorts, which submit information in a standardised format 11 to one of two regional coordinating centres, where error checks are done before data are merged into cohort data and added to COHERE. Duplicate records from people in more than one cohort were removed. We analysed data added to the COHERE database as part of the PLATO II project in 2010 for previously untreated participants aged 16 or older who started antiretroviral therapy from 1998.
We defi ned virological failure of a drug as plasma HIV-1 RNA loads of more than 500 copies per mL despite 4 months or more of continuous use, irrespective of concomitant use of other drugs in this timeframe. Virological failure of drugs from all three classes was defi ned as virological failure of two NRTIs, one NNRTI, and one ritonavir-boosted protease inhibitor. We refer to this combination as TCVF, although other drugs within these classes might retain antiviral activity (eg, newer protease inhibitors, such as darunavir, and NNRTIs, such as etravirine, which were designed to be not crossresistant to existing drugs in the class). We included patients with TCVF from 2000 onwards in the present analysis if they had at least one plasma viral-load measurement after TCVF between 2000 and 2009.
Statistical analysis
We calculated the proportion of people with virological response (<50 copies per mL) after TCVF for the year 2000-09, using values recorded closest to July 1 for each patient. We assessed trends in viral suppression adjusted for characteristics of people at the time of TCVF that could aff ect the probability of virological response by fi tting a multivariable logistic regression model. We adjusted for sex, transmission group, age, presence of AIDS, CD4 cell count, plasma viral load at TCVF, previous achievement of virological response, and number of drug failures before TCVF. For the adjusted analysis of virological response, we included all plasma HIV RNA 12 corresponding to the clinical part of the US Centers for Disease Control and Prevention defi nition. Person-years of follow-up were censored 6 months after the last measurement of CD4 cell count or viral load, the end of the year used in the analysis, or on Dec 31, 2009, whichever occurred fi rst. For incidence of AIDS, follow-up was censored at death. For death, follow-up was censored on Jan 1, 2009, because otherwise records might have been incomplete for some cohorts. Thus, we only report death rates to 2008. We used multivariable Poisson regression models to assess the trends in the risk of AIDS or death in people with TCVF, with the same covariates as we used for the analysis of viral load. Patient-years with missing CD4 counts were excluded from the analyses.
All tests of signifi cance were two-sided, and p<0·05 was regarded as signifi cant. Analyses were done with SAS software version 9.1 and Stata software version 11.0.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Dominique Costagliola, Rebecca Lodwick, Bruno Ledergerber, and Andrew Phillips had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Two of 28 cohorts in the PLATO II project were paediatric cohorts not included in this analysis. We also excluded two cohorts that had few data for patients aged 16 years or older starting combined antiretroviral therapy and no data for patients with TCVF. By 2010, the PLATO II project contained data for 91 764 individuals, of whom 2722 (3%) had TCVF. Overall, 2709 (>99%) of 2722 people with TCVF in included cohorts had failure in 2000-09, and 2476 (91%) had at least one viral-load measurement after TCVF in this time. 1665 (67%) patients were men, 703 (28%) were men who have sex with men, 528 (21%) were heterosexual men, 637 (26%) were heterosexual women, and 354 (14%) were injecting drug users. At time of TCVF, the median age was 39·5 years (IQR 34·4-45·2), median viral load was 4·0 log 10 copies per mL (3·2-4·8), and median CD4 cell count was 270 cells per μL (147-430). 936 (38%) of 2476 people had had an AIDS defi ning event. We obtained data for 25 685 measurements of plasma viral load after TCVF, with a median of eight measurements (IQR four to 15) per person, of which 9564 (37%) were fewer than 50 copies per mL. The proportion of patients with virological response after TCVF increased from 19·5% for people followed up in 2000 to 57·9% in 2009 (p<0·0001; fi gure).
1 year after TCVF, the estimated proportion of participants with virological response was 17·1% in those who had TCVF in 2000 and 49·2% in those who had TCVF in 2008. Irrespective of the year of TCVF (see webappendix), people followed up to the most recent calendar years had the best outcomes. Table 2 shows the results of the univariable and multivariable models for prediction of virological response. In the multivariable model, male and female heterosexuals and injecting drug users were less likely to achieve virological response than were men who have sex with men. Individuals with a lower viral load and a higher CD4 cell count at time of TCVF were more likely to achieve virological response, whereas people who had never achieved virological response before TCVF were less likely to achieve it. Finally, patients who were followed later (ie, closer to 2009) were more likely to achieve viral suppression. Notably, there was no overlap between the CI of the odds ratios for 2008-09 and those for 2006-07. Results were robust when we used an auto regressive covariance matrix instead of an exchangeable one (webappendix).
In 7777 patient-years of follow-up 311 people had a new AIDS event. (table 4) . People with a higher CD4 cell count at time of TCVF were less likely to die than were those with a low CD4 cell count. After accounting for these variables, the trend noted over time (p=0·023) was no longer signifi cant (p=0·22). To account for the fact that injecting drug users are more likely to die from causes not infl uenced by HIV infection and its treatment, we did a post-hoc sensitivity analysis excluding this group. In this analysis, 120 people Never achieving viral load <50 copies per mL before TCVF (yes vs no) 2·22 (1·78-2·78) <0·0001 1·46 (1·16-1·85) 0·0016
Median viral load at TCVF (per log 10 copies per mL increase)
Median CD4 cell count at TCVF* (per 100 cells per μL increase) 0·65 (0·60-0·70) <0·0001 0·74 (0·68-0·80) <0·0001
TCVF=triple-class virological failure. *Missing for 28 (0·4%) person-years of follow-up. 
Discussion
Between 2000 and 2009, the proportion of people who had virological response after TCVF improved substantially, and there was a concomitant decrease in AIDS incidence. However, we did not note an overall decrease in mortality.
Our aim was to assess whether there was an improvement in outcomes for people who had TCVF in the past decade, and we adjusted our models only for variables measured at the time of TCVF because such characteristics might change with time and aff ect outcomes. With this type of analysis we were able to show if there was, or not, a true trend in time. We chose not to analyse the extent to which the measures of improvements in antiretroviral therapy could statistically explain (ie, remove) the positive trends. This choice was made because we did not have measures of drug adherence or good measures of the presence of viral drug resistance. However, we intend in the future to merge data for viral resistance in our study population to assess trends in detected resistance. Because of our objective, we do not think any other independent variables available at TCVF should have been added in the models. For example, CD4 cell count at treatment initiation, which might have changed dependent on the year and might be associated with any one of the three outcomes, would be strongly correlated with CD4 cell counts at TCVF, so would not be an independent factor.
The positive trends that we noted probably relate to improvements in adherence and management of resistance, increasing availability of new drugs within existing classes (such as the protease inhibitor darunavir and the NNRTI etravirine), and increasing availability of drugs from new classes, making new regimens with minimal cross-resistance possible. 13 The trend for an Our results suggest eff ectiveness at a routine clinical population scale of new antiretroviral drugs in terms of morbidity and rates of virological suppression (panel). In particular, because the risk of death did not seem to increase and was perhaps decreasing in individuals who do not use injecting drugs, this study supports the notion that any adverse eff ects of these new drugs on mortality are outweighed by the benefi ts. The positive trends we reported between 2000 and 2009 in this study probably result from improvements in tolerability and ease of use of drug regimens, 14, 15 and in the availability of drugs with non-overlapping resistance profi les. Our results are consistent with recent studies indicating that the proportion of overall clinic populations with suppressed viral load has increased with time. [16] [17] [18] Although we suggest there was a trend towards a decline in mortality, this fi nding was not signifi cant in multivariable analyses; however, there was a substantial decrease in the rate of new cases of AIDS. The reason for this diff erence might be the small sample size (160 endpoints for death vs 311 for AIDS). In the analysis excluding injecting drug users, the time trend for a decline in death rate approached signifi cance in the multivariable analysis even though its power was smaller than in the overall analysis (120 endpoints instead of 160). Another reason for the absence of a signifi cant response in death rate might be because, between 2000 and 2009, a comparatively small and diminishing proportion of deaths in those with TCVF was caused by AIDS. 19, 20 Thus, there is less room for improvement through increased virological control. Nevertheless, there is evidence that HIV increases the risk of several serious non-AIDS conditions 21 so some decrease with time in death rates from non-AIDS causes would be expected. Such disorders might relate to HIV-induced immune activation and infl ammation, which generally persist in the fi rst few years after virological control, and could partly explain the lesser trend that we noted for risk of death. 22, 23 Furthermore, long-term adverse events might have contributed to the weak trend. We are aware that not all cohorts link their data with national death registries, which might result in an underestimation of mortality. A long delay in ascertainment of deaths could lead to overestimation of any positive trends in mortality. By contrast, ascertainment of AIDS should be high because this outcome is chiefl y diagnosed at the clinics themselves. This reasoning is why we censored data on Jan 1, 2009, for death and report results about death to 2008. Nevertheless, this issue cannot explain weakness of the trend for death.
A low CD4 cell count at TCVF was associated with low probability of virological success and high risk of new AIDS events and death. This result, once again, emphasises the importance of maintenance of a healthy CD4 cell count and of an early identifi cation and treatment of HIV infection.
Despite improvements, viral loads cannot be suppressed for some people with TCVF. This eff ect is probably caused by insuffi cient adherence to drug regimens rather than presence of a virus resistant to all drugs. 24 However, some people do have viruses with resistance to all drugs available in 2009. 25, 26 Whether the improving trend, or even the current rate of viral suppression in 2009, can be sustained in the future is unclear. Continued improvement will likely need continued development of new drugs, which are active against virus with resistance to existing drugs.
COHERE accumulates data from cohorts in most countries in western Europe, and includes data for more than 70% of the patients in care in France, the Netherlands, and Switzerland, and 50% of such patients in the UK. Individuals from these four countries make up two-thirds of our dataset and thus we believe that our results are representative of the trends for these countries, and probably for western Europe as a whole. However, we cannot exclude the possibility that, in these countries, clinics contributing to the cohorts have a higher standard of care and perhaps a greater level of viral suppression than do non-participating clinics.
Panel: Research in context
Systematic review Previous studies that investigated virological or clinical outcomes in people who had virological failure on the original three classes of antiretroviral drugs dealt mainly with people who had started antiretroviral therapy with one or two drugs;
1-4 however, this group is now of decreased relevance. We searched PubMed for articles published in any language between January, 2004, and June, 2011, that investigated virological or clinical outcomes (see webappendix) in people with triple-class virological failure who started treatment when combined therapy with three or more drugs had become the norm (1998); we identifi ed only one such study. 9 Because of its small size (167 people with triple-class virological failure), this study had a little power to assess trends of virological and clinical outcomes after triple-class virological failure.
Interpretation
In western Europe, there has been a striking improvement of virological status of people with triple-class virological failure between 2000 and 2009 in routine clinical practice, especially since 2008, and an accompanying decrease in the rate of AIDS. This eff ect is probably largely due to the fact that, in the same period, several drugs have become available that are easier to use and better tolerated than were existing drugs, and tend to be active against virus resistant to typical fi rst-line and second-line drugs.
Overall, we showed substantial improvements between 2000 and 2009 in virological suppression in people who had virological failure to drugs from the three original classes of antiretrovirals, and accompanying decreases in rates of AIDS. We suggest that the set of available drugs is suffi cient to enable construction of active regimens for most infected people. However, because previously untreated patients who start antiretroviral therapy from 2011 will do so with drugs that are diff erent from those used in 1998-2001, drug resistance profi les will diff er in the future and thus there will be a continuing need for new drugs with non-overlapping resistance profi les.
